Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma

Rhea-AI Summary

Intec Pharma Ltd. (NASDAQ: NTEC) announced a feasibility agreement with GW Research Limited to explore the Accordion Pill platform for a yet undisclosed research program. CEO Jeffrey A. Meckler expressed excitement over the collaboration, highlighting its potential to advance innovative therapeutics. Intec Pharma specializes in developing drugs using its Accordion Pill technology, which aims to enhance the efficacy and safety of existing and new medications. Additional details of the agreement were not disclosed, and a cautionary note regarding forward-looking statements was included in the release.

Positive

• Collaboration with GW Research may open new therapeutic avenues.
• Utilization of Accordion Pill platform reinforces Intec's innovation strategy.

Negative

• Lack of detailed information about the research program raises concerns about transparency.
• Need for ongoing financing and favorable clinical trial results remains a risk.

JERUSALEM, Dec. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited ("GW"), London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program. 

"We are very excited to collaborate with GW," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "Through partnerships such as this, we continue to evaluate the utility of our Accordion Pill (AP) platform in the development of innovative therapeutics."

Additional details of the agreement were not disclosed.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

For more information, visit www.intecpharma.com. 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: our limited operating history and history of operating losses, our ability to continue as a going concern, our ability to obtain 

additional financing, our ability to successfully operate our business or execute our business plan, the timing and cost of our clinical trials, the completion and receiving favorable results in our clinical trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to protect and maintain our intellectual property and licensing arrangements, our ability to develop, manufacture and commercialize our product candidates, the risk of product liability claims, the availability of reimbursement, and the influence of extensive and costly government regulation. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2020 and in other filings that we have made and may make with  the Securities and Exchange Commission in the future.

Intec Pharma Investor Contact:

Will O'Connor 
Stern Investor Relations
+1 212-362-1200 
will@sternir.com 

 

View original content:http://www.prnewswire.com/news-releases/intec-pharma-announces-cannabinoid-research-collaboration-with-gw-pharma-301187976.html

SOURCE Intec Pharma Ltd.

FAQ

What is the recent collaboration announced by Intec Pharma (NTEC)?

Intec Pharma announced a feasibility agreement with GW Research Limited to explore its Accordion Pill platform for an undisclosed research program.

What is the Accordion Pill platform used for?

The Accordion Pill platform is designed to improve the efficacy and safety of existing and developing drugs through an advanced oral drug delivery system.

What does the collaboration with GW Research mean for Intec Pharma (NTEC)?

The collaboration may enhance Intec Pharma's research capabilities and support the development of innovative therapeutics.

What risks are associated with Intec Pharma (NTEC) according to the press release?

The press release mentions risks such as the need for additional financing, success in clinical trials, and regulatory approvals.

When was the collaboration agreement between Intec Pharma and GW Research announced?

The collaboration agreement was announced on December 9, 2020.